Entering text into the input field will update the search result below

Multi Billion Dollar, Multi National Antibiotic R&D Superfund Predicted!

May 28, 2015 5:36 AM ETBAYRY, IPIX
ellaruth profile picture
ellaruth's Blog
148 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

As the below Bayer prediction materializes, how much do you value the PolyMedix portfolio that has been acquired by Cellceutix? CTIX is doing a great job developing this stable of antibacterial and anti fungal compounds.

Bayer (BAYRY:OTCMKTS) CEO: G7 will see creation of multinational antibiotic R&D fund

By Nicole Gray | May 26, 2015

Dive Brief:

  • Citing the high cost of devleoping antibiotics aimed at treating drug-resistant infections, Bayer CEO Marijn Dekkers anticipates the creation of a multinational fund at the upcoming G7 meeting in June, Reuters reports.
  • According to Dekkers, creating four new antibiotics will cost roughly $22.4 billion-too much for any one country or entity to take on given the supply and demand dynamics of these drugs.
  • The World Health Organization has deemed the precipitous increase in drug-resistant superbugs "the single greatest challenge in infectious diseases."

Dive Insight:

Multi-drug resistant pathogens have become a serious challenge for infectious disease specialists. The threats are everywhere in hospital settings and everyday communities. Reports of all kinds of multi-drug resistant organisms are abound, including recent reports of a typhoid superbug-H58-and carbapenem-resistant organisms.

The key to addressing these concerns all along has been a consortium-driven/collaborative approach. If the G7 is able to successfully address the need for funding, it will be an important step in the right direction.

Recommended Reading

Reuters: Bayer CEO sees multinational state aid for antibiotics

Comment Below By Ella Ruth;

Recommended Due Diligence: Research the PolyMedix assets acquisition by Cellceutix (CTIX:OTCMKTS) at www.cellceutix.com Research under Brilacidin. Just think Cellceutix acquired an entire Anti-bacterial, Anti-fungal platform of 9 compounds for less than 5 million dollars US.

Analyst's Disclosure: The author is long 10,000 SHARES OF CTIX.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.